FDA sets Dec. 17 review date after Moderna reports further success with Covid vaccine

Cambridge biotech Moderna Inc. will submit its first-ever application for drug approval today after new trial data shows its Covid-19 vaccine is 94% effective at preventing the virus.  Moderna (Nasdaq: MRNA) identified 196 cases of Covid among the 30,000 participants in its Phase 3 clinical trial, according to data reviewed by an outside safety monitoring board. Approximately 11 of those cases were diagnosed in people who had taken Moderna’s vaccine, while the other 185 cases were found in the…

Click to view original post